Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Open Access
- 9 April 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 28 (11) , 1781-1786
Abstract
Lay Summary: Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.Keywords
All Related Versions
Funding Information
- Takeda Pharmaceuticals
- American College of Gastroenterology
This publication has 24 references indexed in Scilit:
- Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case seriesAnnals of the Rheumatic Diseases, 2022
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel DiseaseGastroenterology, 2021
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant RecipientsNew England Journal of Medicine, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsNew England Journal of Medicine, 2021
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 DosesJAMA, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Anomalous collapses of Nares Strait ice arches leads to enhanced export of Arctic sea iceNature Communications, 2021
- Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2020
- Optimizing Immunization Strategies in Patients with IBDInflammatory Bowel Diseases, 2020